ascopubs.org

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. This is an ASCO Meeting Abstract from the ...
ascopubs.org

INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI ...

Advantages of minimally invasive surgery for remnant gastric cancer: A multi-institutional cohort study. This is an ASCO Meeting Abstract from the 2023 ASCO Gastrointestinal Cancers Symposium. This ...
ascopubs.org

A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma.

Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) ...
ascopubs.org

Primary results of ANZ 1002: Post-operative radiotherapy omission in selected patients with early breast cancer trial (PROSPECT) following pre-operative breast MRI.

Mode of detection of second breast cancers in patients undergoing surveillance after treatment of ductal carcinoma in situ. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...
ascopubs.org

Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial.

Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up. Randomized phase 2 study of gemcitabine with or ...
ascopubs.org

Short-course radiotherapy and subsequent CAPOX plus camrelizumab followed by delayed surgery for locally advanced rectal cancer:Short-term results of a phase II trial.

Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC). This is an ASCO Meeting Abstract from the 2021 ...
ascopubs.org

The SURVIVE study: Liquid biopsy guided surveillance after intermediate- to high-risk early breast cancer.

RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...
ascopubs.org

Axillary surgery efficacy for patients with breast cancer receiving neoadjuvant chemotherapy on NSABP B40 and B41.

A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017.
ascopubs.org

Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma.

Targeting urothelial neoplasia using an investigational virus-like drug conjugate. This is an ASCO Meeting Abstract from the 2022 ASCO Genitourinary Cancers Symposium. This abstract does not include a ...
ascopubs.org

Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer.

Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...
ascopubs.org

Clinical outcomes of tepotinib and immune checkpoint inhibitor therapy for MET exon 14 skipping NSCLC: A multicentric retrospective analysis.

Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a phase Ib/II study: Results from single-arm of non-small-cell lung cancer (NSCLC) ...
ascopubs.org

Nationally representative estimates of the participation of cancer patients in clinical research studies according to the commission on cancer.

Evaluation of real-world cost savings and utilization of biosimilar drugs in a community-based oncology practice. This is an ASCO Meeting Abstract from the 2021 ASCO Quality Care Symposium. This ...